玻璃体腔注射Avastin治疗早产儿视网膜病变分析

The clinical characteristics and treatment outcome of special ROP by Avastin

目的 评估行玻璃体腔药物注射Avastin （bevacizumab,rhuMAb-VEGF）治疗的早产儿视网膜病变（retinopathy of Premature,ROP）病例的临床疗效.方法 对2010年7月至2013年9月在广州市妇女儿童医疗中心眼科就诊的22例行玻璃体腔药物注射Avastin治疗的ROP患儿44只眼的临床治疗经过与疗效.所有患儿经筛查确诊后,在24 h内行玻璃体腔注射Avastin 0.03 ml/次,术后3～15 d行第一次复诊,随访8～21周,平均随访时间15周.结果 AP-ROP完全退化6例12只眼,病情控制2例4只眼.全身情况较差的典型ROP患儿完全退化4例8只眼,病情控制2例4只眼.阈值期ROP患儿完全退化4例8只眼,病情控制4例8只眼.结论 对于AP-ROP患儿、典型ROP患儿,单独给予玻璃体腔注射Avastin,可多次给药,每次治疗期限不超过药物半衰期,能控制病情,基本不需要给予激光治疗.

Objective To study the clinical characteristics and outcome of the special cases of ROP after treated by intravitreal injections of Avastin.Methods A retrospective clinical analysis was performed on the data from 22 cases （44 eyes） of patients with ROP.All patients were treated within 24 hours by intravitreal injections with Avastin of 0.03 ml/eye/dose.Results In group of AP-ROP,6 cases （12 eyes） were stopped,2 cases （4 eyes） were controlled.In group of poor condition,4 cases （8 eyes） were stopped,2 cases （4 eyes） were controlled.In the group of threshold period ROP,4 cases （8 eyes） were stopped,4 cases （8 eyes） were controlled.Conclusions To the AP-ROP patients and typical ROP patients,treated by intravitreal injection can effectively control the development of the disease,in the time before and after 20 days （half-life period of Avastin）,when growth disorder of new blood vessels appeared again.If give children Avastin injection again timely,most of patients won＇t appear large avascular and which needn＇t laser treatment.